AML with t(8; 21)(q22; q22) or inv(16)(p13; q22)/t(16; 16)(p13; q22) is known as CBF-AML. KIT
mutations are common in CBF-AML, which have a worse prognosis.This study is aimed to evaluate
the efficacy of Avapritinib, an highly specific inhibitor of the KIT gene, in CBF-AML with
KIT mutations.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University